Evogene Ltd.
EVGN
Rank in Stocks
#31912
Evogene Ltd. is a computational biology firm specializing in the identification... Evogene Ltd. is a computational biology firm specializing in the identification and advancement of products across human health and agricultural sectors. Its proprietary Computational Predictive Biology (CPB) platform leverages deep biological insights, big data, and artificial intelligence to precisely uncover and guide the creation of life science solutions, including novel microbes, small molecules, and genetic components. The company operates through distinct divisions: Agriculture, Human Health, and Industrial Applications. The Agriculture division concentrates on improving crop performance through the development of advanced seed traits, agricultural chemicals, and biological products for crops like corn, soybean, wheat, rice, and cotton. The Human Health division focuses on pioneering microbiome-based treatments for conditions such as immuno-oncology, gastrointestinal ailments, and antibiotic-resistant infections, and also offers medical cannabis products. The Industrial Applications segment is dedicated to developing improved castor bean varieties for various industrial feedstock requirements. Evogene has a global footprint, conducting business in the United States, Israel, Brazil, and other international markets. It maintains significant partnerships, including agricultural collaborations with BASF SE, Corteva, and Bayer, and a medical cannabis development agreement with Cannbit Ltd. through its subsidiary, Canonic Ltd. Established in 1999, Evogene Ltd. is headquartered in Rehovot, Israel.
Share Price
$0.2875
Last synced: 2026-11-09
Market Cap
$2.35M
Change (1 day)
6.09%
Change (1 year)
-76.81%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Evogene Ltd. (EVGN)
Category
Healthcare
Operating Margin for Evogene Ltd. (EVGN)
Operating Margin as of November 2026 TTM: -1,020.35%
According to Evogene Ltd.'s latest financial reports, its current operating margin (TTM) is -1,020.35%. At the end of 2025 the company had an operating margin of -363.28%.
Operating Margin history for Evogene Ltd. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,020.35% | 180.87% |
| 2025 | -363.28% | 39.21% |
| 2024 | -260.96% | -44.48% |
| 2023 | -470.00% | -70.78% |
| 2022 | -1,608.42% | -51.67% |
| 2021 | -3,328.28% | 39.49% |
| 2020 | -2,385.96% | -15.12% |
| 2019 | -2,810.89% | 145.67% |
| 2018 | -1,144.19% | 76.27% |
| 2017 | -649.13% | 101.31% |
| 2016 | -322.46% | 100.25% |
| 2015 | -161.03% | 53.17% |
| 2014 | -105.13% | 111.96% |
| 2013 | -49.60% | 170.89% |
| 2012 | -18.31% | -14.28% |
| 2011 | -21.36% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.85% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.03% |
BE
|
|
| 29.35% | -100.03% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Evogene Ltd.'s operating margin
What is Evogene Ltd.'s operating margin?
Evogene Ltd.'s operating margin is -1,020.35%, as of Nov 2026.
What was Evogene Ltd.'s operating margin in 2025?
In 2025, Evogene Ltd.'s operating margin was -363.28%, compared with -260.96% in 2024.
How has Evogene Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Evogene Ltd.'s operating margin was highest in 2024 (-260.96%) and lowest in 2021 (-3,328.28%).
How does Evogene Ltd.'s operating margin compare with similar companies?
Evogene Ltd.'s operating margin (-1,020.35%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.